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The reduced folate carrier (RFC), a bidirectional anion trans-
porter, is the major uptake route of reduced folates essential for
a spectrum of biochemical reactions and thus cellular prolifera-
tion. However, here we show that ectopic overexpression of the
RFC, but not of folate receptor , a high affinity unidirectional
folate uptake route serving here as a negative control, resulted in
an 15-fold decline in cellular viability in medium lacking
folates but not in folate-containing medium. Moreover to
explore possible mechanisms of adaptation to folate deficiency
in various cell lines that express the endogenous RFC, we first
determined the gene expression status of the following genes:
(a) RFC, (b) ATP-driven folate exporters (i.e.MRP1,MRP5, and
breast cancer resistance protein), and (c) folylpoly--glutamate
synthetase and -glutamate hydrolase (GGH), enzymes cata-
lyzing folate polyglutamylation and hydrolysis, respectively.
Upon 3–7 days of folate deprivation, semiquantitative reverse
transcription-PCR analysis revealed a specific 2.5-fold
decrease in RFC mRNA levels in both breast cancer and T-cell
leukemia cell lines that was accompanied by a consistent fall in
methotrexate influx, serving here as an RFC transport activity
assay. Likewise a 2.4-fold decrease in GGH mRNA levels and
19% decreased GGH activity was documented for folate-de-
prived breast cancer cells. These results along with those of a
novel mathematical biomodeling devised here suggest that
upon severe short term (i.e. up to 7 days) folate deprivation RFC
transport activity becomes detrimental as RFC, but not ATP-
driven folate exporters, efficiently extrudes folate monogluta-
mates out of cells.Hence down-regulation of RFCandGGHmay
serve as a novel adaptive response to severe folate deficiency.
Reduced folate cofactors play an essential role as one-carbon
donors and acceptors in several crucial intracellular metabolic
reactions (1–6). However, mammalian cells are devoid of the
enzymatic capacity for folate biosynthesis and thus are abso-
lutely dependent on folate uptake from exogenous dietary
sources (7). Therefore, folate deficiencymay impair the de novo
biosynthesis of purines and thymidylate and thereby disrupt
DNA and RNA metabolism, homocysteine remethylation,
methionine biosynthesis, and subsequent formation of S-ad-
enosylmethionine, the universal methyl donor, which in turn
may lead to the impairment of methylation reactions (1–6).
Based on their key role in cellular metabolism, folate cofactors
are efficiently retained in cells via polyglutamylation, an ATP-
dependent reaction in which up to 9 eq of glutamate units are
added to the -carboxyl residue of folate cofactors (8, 9) (see
Fig. 1A).Whereas this reaction is catalyzed by the enzyme folyl-
poly--glutamate synthetase (9), the enzyme-glutamyl hydro-
lase (GGH)2 catalyzes the hydrolysis of these terminal -glu-
tamyl residues from polyglutamylated folates (10). Importantly
the long chain (n 3) folate polyglutamylate derivatives can no
longer be extruded viaATP-dependent efflux transporters such
as the multidrug resistance proteins (MRPs/ABCCs) (11, 12)
and breast cancer resistance protein (BCRP/ABCG2) (13) as
well as through the reduced folate carrier (RFC), a bidirectional
folate transporter (14).
The molecular mechanisms underlying adaptation to folate
deficiency are generally associated with alterations in folate
uptake, ATP-driven folate efflux, intracellular folate retention,
and folate-dependent metabolism. These mechanisms include
(a) altered activity of various folate-dependent enzymes includ-
ing dihydrofolate reductase (15) and thymidylate synthase (16),
(b) augmented polyglutamylation via increased folylpoly--glu-
tamate synthetase activity (17, 18), (c) overexpression of folate
influx systems including the RFC (SLC19A1) (16, 19) and the
folate receptor (FR) (15, 17, 20), and (d) down-regulation of
ATP-dependent folate exporters of theMRP/ABCC family (21,
22) as well as BCRP/ABCG2 (18, 23).
RFC, the main focus of this study, serves as the major uptake
route of folates in mammalian cells (14).Whereas RFC exhibits
a relatively wide pattern of tissue expression, the expression of
the additional folate uptake systems including the FR family
(19, 24–35) and the proton-coupled folate transporter (PCFT/
SLC46A1) (36–40), both of which are unidirectional transport
systems, is rather restricted to a limited number of tissues. Con-
sistently in vivo studies have revealed that whereas RFC-null
embryos died in utero prior to embryonic day 9.5 the rescue of
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supplementation of pregnantmonoallelic RFC damswith 1-mg
daily subcutaneous doses of folic acid (41). Furthermore the
rescued RFC nullizygous embryos died within 12 days after
birth due to a failure of hematopoietic organs (41).
RFC functions as a bidirectional anion exchanger (36, 42)
with a high affinity (Km 1 M) for reduced folates and hydro-
philic antifolates such as methotrexate (MTX; Km 5–10 M)
but very low affinity (Km 200–400M) for folic acid (42–44).
RFC can neither bind nor hydrolyze ATP to drive its folate
transportactivityacross theplasmamembrane.Rather theRFC-
dependent uphill influx of folates is coupled to the downhill
efflux of organic phosphates including thiamine monophos-
phate and pyrophosphate (45) that are readily available in the
cytoplasm.
In the current study we hypothesized that under conditions
of severe folate deprivation the folate efflux component of RFC
transport activity may result in intracellular folate depletion
and consequently decreased cellular viability. Based upon
experimental results as well as on novel mathematical biosimu-
lation data, we show here for the first time that upon short term
(i.e. up to 7 days) exposure of cells to folate-free growth condi-
tions, RFC-dependent folate efflux activity becomes detrimen-
tal as RFC extrudes folate monoglutamates out of cells, a proc-
ess facilitated by the GGH-dependent conversion of folate
polyglutamates to monoglutamates. Moreover this cytotoxic
folate efflux activity may be abrogated by specific adaptive
down-regulation of both RFC and GGH via decreased gene
expression and subsequently decreased catalytic activities;
indeed this novel survival response to folate-deprived condi-
tions has been established here for T-cell leukemia CEM/7A
cells with overexpression of the endogenous RFC (19) as well as
for the breast cancer MCF7/MR cells that expresses only mod-
erate levels of this double edged sword transporter.
EXPERIMENTAL PROCEDURES
RFC-dependent Cellular Viability in the Presence or Absence
of Folates
The Chinese hamster ovary cell line deficient in RFC activity
termed C5 (46) as well as its human RFC- and human FR-
overexpressing transfectants (i.e. C5/RFC and C5/FR, respec-
tively (46)) were trypsinized and washed three times with folic
acid-free growth medium. Then cells (6 104) were seeded in
each of twoT25 flasks in 5ml of folic acid-free growthmedium.
The sublines in the first set of flasks were termed C5/NF,
C5/RFC-NF, and C5/FR-NF (i.e. no folate), whereas the sub-
lines in the second set of flasks were supplemented with folate
derivatives according to their initial growth conditions (46),
resulting in the sublines C5-HF (i.e. high folate; supplemented
with 2.3 M folic acid), C5/RFC-3nMLCV (i.e. supplemented
with 3 nM leucovorin, whichwas used as a folate source because
of its high affinity to the RFC when compared with folic acid),
C5/FR-3nMFA (i.e. supplemented with 3 nM folic acid, which
was used as a folate source because of its high affinity to the FR
when compared with Leucovorin (LCV)). All six flasks were
simultaneously incubated for 6 days in a humidified CO2 incu-
bator without medium replenishment in each of three inde-
pendent experiments. Following these 6 days of incubation,
cells were detached by trypsinization, and the number of viable
cells was determined by hemocytometer counting after trypan
blue staining.
Folate Deprivation
The following are the folate deprivation protocols that we
have developed for the following cell lines to explore possible
mechanisms of adaptation to folate deficiency.
MCF7/MR Cells (with Moderate Levels of the RFC)—
MCF7/MR cells were grown as described previously (18). Fol-
lowing trypsinization, cells were washed three times with folic
acid-free growth medium containing 10% dialyzed fetal calf
serum and antibiotics. Then cells (2.3  105) were seeded in
each of two T75 flasks in 15 ml of folic acid-free growth medi-
um; the subline in the first flask was therefore termed MCF7/
MR-NF, whereas the second flask was supplemented with 2.3
M folic acid and was thus termed MCF7/MR-HF. Following 3
days of incubation, cells were then ready for the various analy-
ses including semi-quantitative RT-PCR and determination of
initial rates uptake of [3H]MTX and GGH activity.
CEM/7A Cells (with Overexpression of the RFC)—CEM/7A
cells were cultured in growth medium containing 0.2 nM LCV
as has been described previously (19). Cells were then washed
three times with folic acid-free growthmedium containing 10%
dialyzed fetal calf serum and antibiotics and transferred (107
cells) to each of two T75 flasks in 50ml of folic acid-free growth
medium containing 10% dialyzed fetal calf serum and antibiot-
ics; the subline in the first flask was termed CEM/7A-NF,
whereas the second T75 flask was supplemented with 0.2 nM
LCV and was therefore termed CEM/7A-HF. Following 7 days
of incubation, cells were then ready for the various analyses
including semi-quantitative RT-PCR and determination of ini-
tial rates uptake of [3H]MTX and GGH activity.
RNA Extraction and Semiquantitative RT-PCR
Total RNA extraction followed by cDNA synthesis was
undertaken as described previously (47). To evaluate the levels
of -actin, glyceraldehyde-3-phosphate dehydrogenase, BCRP,
MRP5, MRP1, GGH, folylpoly--glutamate synthetase, PCFT,
FR, and RFC gene expression, semiquantitative RT-PCR anal-
ysis was used. PCR was carried out in a total volume of 30 l in
the presence of the following cDNA quantities (using 6-fold
serial template dilutions): 100, 16.7, and 2.8 ng. Each PCR con-
tained a 0.4 M concentration of the sense and antisense prim-
ers (see Table 1) and 1 REDTaqTM ReadyMixTM PCR reac-
tionmixture (Sigma). Following an initial denaturation at 95 °C
for 10min, 24–35 cycles each of 1min of denaturation at 95 °C,
1 min of annealing at 50–61 °C (Table 1), and 1 min of elonga-
tion at 72 °C aswell as a final extension period of 10min at 72 °C
were carried out. PCR products were analyzed by electrophore-
sis on 1–2% agarose gels. Representative results of three inde-
pendent experiments are shown.
Determination of Initial Rates of [3H]MTX Uptake
Following the folate deprivation protocols, [3H]MTX influx
was determined as described previously (46). The advantage of
usingMTX rather than folic acid is its 40–80-fold higher affin-
ity to RFC when compared with folic acid (42–44).
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GGHActivity Assay
Catalytic GGH activity assay was measured according to the
original protocol described by O’Connor et al. (48) with some
slightmodifications (49). These protocols are based on the abil-
ity of GGH to convert MTX-Glu2 toMTX (48, 49). GGH activ-
ity is expressed as nmol of MTX formed/h/mg of protein.
Mathematical Biomodeling of Intracellular Folate Depletion
Here we devised a mathematical biomodeling aimed at
evaluating the intracellular folate pool-depleting effect of
the RFC as well as of several representatives of the ATP-
binding cassette (ABC) transporter superfamily (i.e. MRP3
and MRP4) under folate-free growth conditions (Fig. 1B).
The above mentioned folate efflux systems transport intra-
cellular monoglutamylated folates to the extracellular com-
partment, which is literally infinite relative to the intracellu-
lar volume. Thus, the influx of the transported folates is
negligible and can be omitted in the model. We applied the
Michaelis-Menten equations (67) to simulate these efflux
transport activities.
Hence the efflux velocity (V) can be derived from the basic
enzymatic reaction kinetics where a substrate S is converted to
a product P as follows according to the equation
Vt 
Vmax  S
Km S
(Eq. 1)
where S is the concentration of the substrate, Vmax is the limit-
ing velocity value at substrate saturation (i.e. when [S] Km),
andKm is the substrate concentration whenVVmax/2. In our
model, t The duration of time (in minutes) in which the cells
have been exposed to the folate-free growth conditions. Vt 
The efflux velocity (mol/liter/min which is M/min) of the
examined transporter at time t. [S]t [MonoFP]t The cyto-
solic concentration (M) of the monoglutamylated folate pool
at time t. Vmax  The maximum folate efflux velocity of the
examined transporter (M/min).KmThemonoglutamylated
reduced folate concentration (M) of the examined transporter
in whichVVmax/2. Inserting the last series of definitions into
Equation 1 results in the following.
Vt 
Vmax  MonoFPt
Km MonoFPt
(Eq. 2)
[TFP]t the intracellular concentration of the total folate pool
(M) at time t. However, the cytosolic fraction of folates in
mammalian cells is only 38%of the total folate pool size (50, 51).
Moreover the cytosolic monoglutamate folate fraction, which
serves as the available folate efflux fraction for RFC as wells as
for several ABC transporters, is only 2% of the total cytosolic
folate pool inmammalian cells (50, 51). Therefore, the cytosolic
monoglutamylated folate fraction is only 0.76% of the total
intracellular folate pool size under folate-replete conditions.
Based upon the essential lack of folates in the extracellular
medium under folate-free growth conditions along with the
continuous efflux of cytosolic folate monoglutamates via the
examined transporter as well as based on the Le Chatelier prin-
ciple, one could predict a continuous conversion of intracellu-
lar folate polyglutamates tomonoglutamate congeners via lyso-
somal GGH activity (see Fig. 1B) in an attempt to retain the
original fraction (i.e. 0.76%) of the monoglutamylated folate
pool (i.e. [MonoFP]t) relative to the total intracellular folate
pool (i.e. [TFP]t). Whereas the kinetic understanding of mito-
chondrial influx as well as efflux of folates is limited and based
upon the above mentioned experimental data as well as on the
Le Chatelier principle, we used the calculated cytosolic mono-
glutamylated folate fraction of 0.76% in this theoretical model-
ing as follows.
Vt 
0.0076  Vmax  TFPt
Km 0.0076  TFPt
(Eq. 3)
The [TFP]t is equal to the initial total folate pool (i.e. [TFP]t 0)
from which the amount of monoglutamylated folates that has
been transported via the examined transporter was subtracted
until time t (minutes) as described in the following equation.
TABLE 1
Oligonucleotides used for semiquantitative RT-PCR
FPGS, folylpoly--glutamate synthetase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Gene Primers: sense primer (S),antisense primer (AS) Annealing temperature Number of cycles Product length Ref.
°C bp
RFC 5-AGCCTCCCTGGAGCAGAGAC-3 (S),
5-ACTCCTGTGGGGCCAGTGTC-3 (AS)
58 24–30 619
FR 5-CCAGCAGGTGGATCAGAGCTG-3 (S),
5-CGACCATGGAGCAGGAACC-3 (AS)
61 34 510
PCFT 5-ATGCAGCTTTCTGCTTTGGT-3 (S),
5-GGAGCCACATAGAGCTGGAC-3 (AS)
55 35 100 56
FPGS 5-CCGGCTGAACATCATCCA-3 (S),
5-CTTTCTGCCATGCGATCTTCT-3 (AS)
60 28 449 63
GGH 5-GCTTATTAACTGCCACAGATACGTTG-3 (S),
5-GAACATTCTGCTGTGCAATGAC-3 (AS)
50 30 79 64
MRP1 5-CAGGAGCAGGATGCAGAGGA-3 (S),
5-TGTAGTCCCAGTACACGGAAAGC-3 (AS)
60 28 280 63
MRP5 5-CCCAGGCAACAGAGTCTAACC-3 (S),
5-CGGTAATTCAATGCCCAAGTC-3 (AS)
58 30 112 65
BCRP 5-TGCCCAAGGACTCAATGCAACA-3 (S),
5-ACAATTTCAGGTAGGCAATTGTG-3 (AS)
60 27 172 66
GAPDH 5-AGGGGGGAGCCAAAAGGG-3 (S),
5-GAGGAGTGGGTGTCGCTGTTG-3 (AS)
60 35 514 63
-actin 5-CCGTCTTCCCCTCCATCGTG-3 (S),
5-GGGCGACGTAGCACAGCTTCT-3 (AS)
56 28 576 63
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TFPt TFP0 
x 0
x t
0.0076  Vmax  TFPx
Km 0.0076  TFPx
 dx (Eq. 4)
Km 0.0076[TFP]x	 0. This condition is true because of the
fact that the Km of the examined transporters has a positive
value, and [TFP]x  0 for t  x  0. Hence
(0.0076Vmax[TFP]x)/(Km  0.0076[TFP]x) is a continuous
function for t x 0, and thus according to the first part of the
fundamental theorem of calculus we may differentiate both
sides of the equation (with regard to t) as follows.
dTFPt
dt


0.0076  Vmax  TFPt
Km 0.0076  TFPt
(Eq. 5)
This is a separable differential equation that can be written as
follows.
dt

Km 0.0076  TFPt
0.0076  Vmax  TFPt
 dTFPt (Eq. 6)
Integration of both sides of the equations results in the follow-
ing equation.
t  

0.0076  TFPt Km  ln
TFPt
0.0076  Vmax
 constant (Eq. 7)
The total intracellular folate pool size of cultured mammalian
tumor cells (i.e. [TFP]t 0) was experimentally found to be
11.3 M (52); using these empirical data results in the follow-
ing equation.
0  

0.0076  11.3 Km  ln
11.3
0.0076  Vmax
 constant (Eq. 8)
Hence the following relation describes each biosimulation.
constant
0.0859 Km  2.4248
0.0076  Vmax
(Eq. 9)
The mathematical expression that describes the constant (i.e.
Equation 9) can be used in Equation 7 as follows.
t  

0.0076  TFPt Km  ln
TFPt
0.0076  Vmax

0.0859 Km  2.4248
0.0076  Vmax
(Eq. 10)
Rearrangement of Equation 10 results in the following
equation.
t 
0.0859  Km  2.4248  0.0076  TFPt Km  ln
TFPt
0.0076  Vmax
(Eq. 11)
This final implicit function (i.e. Equation 11) demonstrates the
relation between the total intracellular folate pool (i.e. [TFP]t)
and the duration of folate deficiency (t inminutes) for an exam-
ined transporter with affinity for reduced folate (i.e. Km in M)
and the maximum folate efflux velocity (i.e. Vmax in M/min).
The Km and Vmax of the various folate efflux systems have been
derived in previous publications from cells that overexpress the
examined transporter. These experiments yielded reliable
results for the Km; however, the calculated Vmax does not rep-
resent a physiologic value. Hence we used the human leukemia
CCRF-CEM cells that express normal levels of the RFC along
with several members of the ABC superfamily including sub-
stantial levels ofMRP1 andMRP4 (21) to derive the total typical
capacity of folate efflux in mammalian cells. Hence given that
the experimental Vmax is 4 pmol/(107 cellsmin) for a folate-
based compound (19) and that the reported cell volume for
CCRF-CEM cells is 4  10 
10 ml/cell (36), we found that the
typical maximal capacity (i.e. Vmax) of folate efflux in these
mammalian cells is exactly 1 M/min. During previous studies,
a reduction of 60% in the folic acid efflux rate constant was
documented in the presence of the RFC transport inhibitor
N-hydroxysuccinimide ester of MTX (21). Therefore, the esti-
mated capacity of RFC is 0.6 M/min, whereas the remaining
folate efflux systems have a cellular folate efflux capacity of 0.4
M/min. These estimated folate efflux capacities were used to
evaluate the folate efflux contribution of RFC relative to the
remaining ATP-driven folate efflux systems in the current bio-
simulation. However, to thoroughly investigate the folate
depleting nature of these efflux transporters, four hypothetical
efflux capacitieswere used for several transporters as follows: 1)
1 M/min, 2) 10
1 M/min, 3) 10
2 M/min, and 4) 10
3
M/min. The theoretical experiments were conducted to char-
acterize the folate-depleting effect of RFC with a high affinity
(Km 1M) for reduced folates, which serve as the main intra-
cellular folate derivatives, when compared with two represen-
tatives of theABC transporters includingMRP3withKm 1.74
mM for reduced folates (11, 53) and MRP4 with Km 0.64 mM
for reduced folates (53, 54). These representatives of the ABC
transporters were chosen because of available kinetics data (i.e.
Km) for the reduced folate derivatives that serve as the domi-
nant intracellular folate fraction. The various graphs were plot-
ted in a single coordinate system using the Graph 4.3 software.
Statistical Analysis
We used a paired Student’s t test to examine the significance
of the difference between two populations for a certain variable.
A difference between the averages of two populations was con-
sidered significant if the p value obtained was0.05.
RESULTS ANDDISCUSSION
In mammalian cells, the transport of tetrahydrofolate
cofactors (i.e. a reduced folate derivative) proceeds primarily
via the RFC, a high affinity transporter of naturally occurring
reduced folates (e.g. Km  1 M for 5-methyltetrahydrofo-
late). RFC is a non-concentrative, facilitative transporter
with the characteristics of a bidirectional anion exchanger
that equally displays influx and efflux of reduced folates. We
hence postulated here that the high affinity folate efflux
activity component of the RFC may be detrimental to cells
subjected to folate-free conditions. The rationale behind this
hypothesis was that under these conditions of folate depri-
vation RFC would extrude reduced folate monoglutamates
out of cells. Given the lack of folates in the extracellular
RFC and Detrimental Folate Efflux
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medium under conditions of severe folate deprivation along
with the high affinity RFC-dependent efflux of folate mono-
glutamates and based upon the Le Chatelier principle, one
could predict a continuous conversion of intracellular folate
polyglutamates to monoglutamate congeners via lysosomal
GGH activity (Fig. 1B). This should result in the continuous
efflux of folate monoglutamates via RFC thereby leading to
decreased intracellular folate pool and consequent loss of
cellular viability (Fig. 1B and Fig. 2). Furthermore the folate
influx component of the RFC becomes useless when folates
are absent from the growth medium, hence rendering RFC a
high affinity unidirectional folate exporter (Fig. 1B). To
explore this hypothesis that RFC exerts a cytotoxic effect
under conditions of folate deficiency, we first compared the
viability of three sublines in medium containing or lacking
folates; these cell lines included RFC-null Chinese hamster
ovary C5 cells, their stable C5/RFC transfectants overex-
pressing the RFC (46), and C5/FR transfectants overexpress-
ing FR, the latter of which lacks folate efflux activity and
thus serves as a negative control to the efflux component of
the RFC (Fig. 2). The principal advantage of using this par-
ticular panel of cell lines is that they are devoid of endoge-
nous RFC transport activity (46). Moreover to investigate the
possible cytotoxic effect of the RFC we preferred to use
C5/RFC cells with ectopic RFC overexpression driven by a
dominant cytomegalovirus promoter (46) rather than an
endogenously overexpressed RFC that may be down-regu-
lated via a protective mechanism and thereby may compro-
mise this cytotoxic effect. The results revealed a similar via-
bility of C5, C5/RFC, and C5/FR cells in folate-replete
growth medium (i.e. C5-HF, C5/RFC-3nMLCV, and C5/FR-
3nMFA, respectively) (Fig. 2). In contrast, in folate-free
medium, the viability of C5/RFC cells (i.e. C5/RFC-NF), but
not C5/FR-NF cells, was 14.8-fold decreased (p  0.025)
relative to RFC-null C5 cells (i.e. C5-NF) (Fig. 2). Therefore,
these results strongly suggest that RFC-mediated folate
efflux activity is responsible for the deleterious effect on cel-
lular viability under conditions of severe folate deprivation.
Whereas RFC transfectant C5/RFC cells were instrumental
in demonstrating the cytotoxic effect of RFC under folate
deficiency conditions, we further explored possible mecha-
nisms of adaptation to folate deficiency in various cell lines
displaying endogenous RFC expression, thus enabling us to
identify a possible programmed protective response(s) to
folate deficiency. Toward this end, we used T-cell leukemia
CEM/7A cells with overexpression of the endogenous RFC
(19) as well as breast cancer MCF7/MR cells expressing only
moderate RFC levels. The latter cell line was specifically cho-
sen as it co-expresses various folate influx and efflux trans-
porters; we therefore determined which of these folate
FIGURE 1.Model of intracellular folatemetabolism under replete (A) and
depleted conditions (B). FPGS, folylpoly--glutamate synthetase.
FIGURE 2. Viability of RFC-overexpressing cells versus RFC-null cells
under short term folate deficiency. The Chinese hamster ovary cell line
deficient in RFC transport activity termedC5 and its RFC- and FR-overexpress-
ing transfectantswere trypsinizedandwashed three timeswith folic acid-free
growthmedium. Then cells (6 104) were seeded in each of two T25 flasks in
5 ml of folic acid-free growth medium. The sublines in the first set of flasks
were termed C5/NF, C5/FR-NF, and C5/RFC-NF (i.e. no folate). The sublines in
the second set of flaskswere supplementedwith folate derivatives according
to their initial growth conditions (i.e. 2.3M folic acid, 3 nM folic acid, and 3 nM
LCV) resulting in the sublines C5-HF, C5/FR-3nMFA, and C5/RFC-3nMLCV,
respectively. All six flasks were simultaneously incubated for 6 days in a
humidified CO2 incubator at 37 °C. Following these 6 days of incubation, cells
were detached by trypsinization, and the number of viable cells was deter-
mined by hemocytometer counting after trypan blue staining. The star
denotes a statistically significant difference. Error bars indicateS.D. of each
series of measurements for each cell line.
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transporters may be down- or up-regulated upon short term
folate deprivation. Semiquantitative RT-PCR analysis re-
vealed a specific 2.4-fold (p  0.01) and 2.6-fold (p  0.005)
decrease in RFC and GGHmRNA levels, respectively, upon 7
days of folate deprivation in breast cancer MCF7/MR cells
(i.e. MCF7/MR-NF versus MCF7/MR-HF); 7 days were the
minimal duration time of folate deficiency that enabled us to
detect a statistically significant difference in the expression
of one or more genes in this cell line (Fig. 3). Similarly RFC-
overexpressing CCRF-CEM/7A leukemia cells (19) dis-
played a specific 2.5-fold decrease (p 0.009) in RFCmRNA
levels after 3 days of incubation in folate-free medium (i.e.
CEM/7A-NF versus CEM/7A-HF; Fig. 3); in these cells, 3
days were the minimal duration time of folate deficiency that
yielded a statistically significant difference in RFC gene
expression. The stable gene expression status of the addi-
tional folate uptake systems including FR (19, 24–35) and
PCFT (36–40) (Fig. 3) strongly suggests that the folate efflux
component of RFC was detrimental to cells upon folate defi-
ciency rather than its folate influx component. This 2.5-
fold decrease in RFCmRNA levels in both breast cancer cells
and T-cell leukemia lines under folate deficiency was then
examined at the transport activity level (Fig. 4); the initial
rates of [3H]MTX uptake were determined in the two folate-
deprived cell lines. Consistent with the decreased RFC tran-
script levels in folate-deprived cells, both MCF7/MR
(expressing low levels of RFC) and CCRF-CEM/7A cells
(overexpressing the RFC) showed a 49% (p  0.03) and 44%
(p  0.004) decrease in the influx of [3H]MTX under condi-
tions of folate deprivation, respectively (Fig. 4, A and B).
Thus, the cytotoxic effect of the RFC upon folate-deficient
conditions was probablyminimized because of the decreased
RFC transport activity. Likewise the 2.4-fold decrease in
GGH mRNA levels was accompanied with 19% decreased
GGH activity (p 0.025; Fig. 5A) for folate-deprived MCF7/
MR-NF cells relative to their folate-replete counterparts.
This specific down-regulation of both RFC and GGH gene
expression and activity may serve as a novel cellular adap-
tive-protective response under folate-deficient conditions
aimed at counteracting the detrimental conversion of folate
polyglutamates to monoglutamates and their subsequent
high affinity extrusion via the RFC. Further studies are war-
ranted to pinpoint the putative RFC and GGH promoter ele-
ments that may respond to folate deprivation and thereby
result in repression of gene expression in medium lacking
FIGURE 4. [3H]MTX transport in folate-supplemented and -deprived sub-
lines. Initial rates of [3H]MTX uptake were determined for the folate-supple-
mented cell lines MCF7/MR-HF (A) and CEM/7A-HF (B) as well as for their
folate-deprived counterparts MCF7/MR-NF and CEM/7A-NF sublines, respec-
tively. Note that the star denotes a statistically significant difference, whereas
the average percent decrease of initial rates of [3H]MTX uptake is depicted
within the figure and shown adjacent to the relevant column. Error bars indi-
cateS.D. of each series of measurements for each cell line.
FIGURE 5.GGH activity in folate-supplemented and folate-deprived sub-
lines. GGH activity was determined for the folate-supplemented cell lines
MCF7/MR-HF (A) and CEM/7A-HF (B) as well as for their folate-deprived coun-
terparts MCF7/MR-NF and CEM/7A-NF, respectively. Note that the star
denotes a statistically significant difference, whereas the average percentage
decrease of GGH activity is depicted within the figure and shown adjacent to
the relevant column. Error bars indicateS.D. of each series ofmeasurements
for each cell line.
FIGURE 3.Gene expression status of folate influx and efflux transporters
aswell as folate-dependentenzymesunder folate-depletedand -replete
conditions. Total cellular RNA was extracted from the folate-supplemented
cell lines MCF7/MR-HF and CEM/7A-HF as well as from their folate-deprived
counterparts MCF7/MR-NF and CEM/7A-NF cells, respectively. Then the tran-
script levels of -actin, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), BCRP, MRP5, MRP1, GGH, folylpoly--glutamate synthetase (FPGS),
PCFT, FR, and RFC in the various sublines were quantified by semiquantitative
RT-PCRanalysis. Signal intensitywasquantifiedusingthedensitometricprogram
TINA (version 2.10g). After normalizing versus glyceraldehyde-3-phosphate
dehydrogenaseand-actin levels,average-folddecrease (asdepictedwithinthe
figure and located adjacent to the relevant gene) was determined. Each experi-
mentwas repeated three times. Moreover each semiquantitative RT-PCR exper-
iment was done in a titration manner (i.e. 1, 1:16, and 1:36 using 6-fold serial
template dilutions) to identify and exclude signals originating from the plateau
phase. Note that in contrast toMCF7/MR the gene expression levels of FR, PCFT,
MRP5, and BCRP in CCRF-CEM/7A cells is negligible.
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folates. The fact that neither of the ATP-driven folate
exporters including MRP1, MRP5, and BCRP (11, 12, 53, 55)
underwent down-regulation under these folate-depleted
conditions (Fig. 3) suggests an augmented detrimental role
for RFC-dependent high affinity folate efflux activity relative
to the above ATP-driven, low affinity (e.g. transport Km val-
ues for folic acid in the millimolar range) efflux transporters
of the ABC superfamily (53) (Figs. 1B and 6). However, in an
attempt to provide a comparative quantification of the intra-
cellular folate-depleting effect of RFC with those of ATP-
driven folate exporters, we devised a novel mathematical
biomodeling (Fig. 6). The in silico experiments showed 10-
and 100-fold decreases in the intracellular folate pool within
8.7 and 17.1 h under folate-free growth conditions, respec-
tively, as a result of the estimated cellular efflux activity of
RFC (i.e. 0.6 M/min as was calculated under “Experimental
Procedures”; Fig. 6). Furthermore the activity of RFC
resulted in a dramatic contraction in the intracellular folate
pool within days (i.e. 10- and 100-fold decreases in the intra-
cellular folate pool within 2.2 and 4.3 days, respectively) if
only 10% of the cellular efflux capacity (i.e. 0.1 M/min) was
attributed to this transporter (Fig. 6). In contrast to RFC, the
folate efflux activity of MRP3 and MRP4 resulted in the
retention of the vast majority of the intracellular folate pool
(i.e. 96 and 89% retention, respectively) after 7 days of incu-
bation in folate-free medium (Fig. 6). This lack of a substan-
tial folate-depleting effect was observed even when the com-
plete cellular folate efflux capacity (i.e. 1 M/min) was
attributed to each of the two ABC transporters (Fig. 6).
Hence these results provide a mechanistic basis for the
highly specific down-regulation of the cytotoxic efflux activ-
ity of the RFC but not of folate exporters of the ABC super-
family (Fig. 3) that failed to cause any major decrease in the
intracellular folate pool (Fig. 6) upon short term (up to 7
days) folate deprivation. However, the medium term and
long term (i.e. weeks and months, respectively) folate-de-
pleting effect of several transporters of the ABC superfamily
has been suggested previously to be detrimental to cells
under folate-deficient conditions (18, 21, 23). Indeed our
mathematical biomodeling reveals that the folate efflux
activity of MRP4, as a representative of folate exporters of
the ABC superfamily, may be responsible for a 30% decrease
in the intracellular folate pool within 3 weeks of exposure to
folate-free growth conditions; this moderate depleting effect of
this ABC transporter may contribute to the detrimental effect of
medium term and long term folate deprivation. Collectively our
findings strongly suggest that the bidirectional folate transport
activity ofRFC is responsible for its double edged sword impact on
folatehomeostasis.Moreover it ispossible that theability todown-
regulate RFC and GGH gene expression under states of severe
folate deprivation stems from evolutionary roots originating in
unicellular organisms and perhaps metazoic ancestral organisms
undergoing transient yet frequent states of starvation and severe
folate deprivation. One important emerging question from the
current study is what physiological-pathological conditions and
syndromes could match the transient folate deprivation condi-
tions used in the current study. The first pathological syndrome,
hereditary folate malabsorption (56), is caused by loss of function
mutations in the proton-coupled folate transporter (PCFT/HCP-
1/SLC46A1) normally responsible for the high affinity intestinal
influx of naturally occurring folates in the acidic microclimate of
the upper intestinal mucosal epithelium. Hence hereditary folate
malabsorption patients suffer from extremely low folate levels
(	0.2 nM) in the blood and cerebrospinal fluid (40, 56). Another
physiological-pathological condition thatmaymatchsuchasevere
folate deprivation state is nutritional folate deficiency or insuffi-
ciency. Indeed folate deficiency affects10% of the population as
well as more than 50% of the children and elderly that live in pov-
erty in theUnited States, Thailand, and rural areas of India (38, 57,
58). Hence under such physiological-pathological conditions of
severe folate deficiency, RFC and GGH may possibly undergo a
significantdown-regulation ingeneexpressionandactivity topro-
tect cells from further loss of intracellular folates due to folate
efflux via the RFC.
The current study may have profound implications relating
to various disciplines in biology and medicine including the
following. (a) In regard to developmental biology and embry-
onic development, the central developmental role that mam-
malian RFC plays has been revealed in RFC knock-out mice
studies (41). In contrast to this vital role of the RFC under con-
ditions in which folates are available for the pregnant dams, our
findings suggest that under conditions of severe nutritional
folate deficiency or insufficiency of mammalian pregnant dams
the RFC may in fact exacerbate the pathological status of the
embryos caused by the folate deficiency by further extruding
folates. Thus, RFC may play a key role in inducing early abor-
tions during early stages ofmammalian pregnancywhen folates
are severely limited in the growth environment and thereby
may confer an evolutionary advantage by eliminating embryos
that are certain to fail at normal cell proliferation, differentia-
tion, and proper development. (b) In regard to molecular med-
icine, RFC is an important route for the uptake of various anti-
FIGURE 6. Mathematical biomodeling of intracellular folate pool deple-
tion by folate efflux transporters. Shown is the mathematical modeling
aimed at evaluating the residual intracellular folate pool (y axis) in the pres-
ence of the following folate efflux transporters: RFC, MRP3, or MRP4. The
differentmaximal folate efflux capacities for each experiment are depicted in
closeproximity to its plottedgraphor viaarrows. The theoretical experiments
simulate the cellular folate pool status for duration of up to 7 days (x axis)
upon folate-free conditions in the presence of one examined folate efflux
transporter. Note that the folate-depleting effect of the RFCwas evaluated in
four different efflux capacities including the hypothetical negligible capaci-
ties of 1 and 0.1% (i.e. 0.01 and0.001M/min, respectively) of the total cellular
folate efflux capacity.
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folates including for example MTX and pemetrexed (Alimta)
(59, 60). Hence our findings suggest that the down-regulation
of the RFC as a result of folate-deficient conditions may
decrease antifolate uptake and thus compromise the pharma-
cological efficacy of antifolates currently used in chemotherapy
of various cancers. Moreover down-regulation and mutational
inactivation of the RFC serve as major mechanisms of antifolate
drug resistance exhibited by cancer cells (47, 59, 61, 62). Hence
antifolate-resistant cancer cells may readily survive not only the
exposure to antifolates but also transient folate deficiency due to
themarkedly decreased folate efflux via the RFC.
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